Background
NSCLC, tumor, cancer, mCRC, non-squamous non-small cell lung cancer
METASTATIC COLORECTAL CANCER, TUMOR, GLIOBLASTOMA MULTIFORME, FALLOPIAN TUBE CANCER, CANCER, METASTATIC RENAL CELL CARCINOMA, CERVICAL CANCER, EPITHELIAL OVARIAN CANCER, NSCLC, TUMOR GROWTH, NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, METASTATIC BREAST CANCER
Bevacizumab (Avastin®), produced in Chinese hamster ovary cells using DNA technology, is a recombinant humanized immunoglobulin G1 monoclonal antibody. Bevacizumab works by preventing vascular endothelial growth factor (VEGF) from binding to its receptors (Flt-1 and KDR) on the surface of endothelial cells, preventing angiogenesis and tumor growth [Avastin®, initially approved by the U.S. Food and Drug Administration (FDA) in 2004 in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC) as a first- or second-line approach, was one of the first targeted therapies and the first approved angiogenesis inhibitor. In 2005, the European Union (EU) granted Avastin® marketing authorization for the first-line treatment of patients with mCRC combining with chemotherapy. Since then, a variety of oncology indications have been approved worldwide, including but not limited to mCRC, non-squamous non-small cell lung cancer (NSCLC), metastatic renal cell carcinoma, glioblastoma multiforme (the U.S. only), epithelial ovarian cancer, fallopian tube cancer, cervical cancer, primary peritoneal cancer, and metastatic breast cancer (EU only) [Although bevacizumab has been approved for various tumor indications and its efficacy has been demonstrated, its high treatment cost limits its use by most patients with cancer [Biosimilars are therapeutic biologic products that are highly similar in product purity, safety, or potency to a licensed biologic (i.e., reference or originator) [